GLP-1 Eligibility Checker

Check if you may qualify for GLP-1 weight loss medications like Ozempic, Wegovy, Mounjaro, or Zepbound based on FDA clinical guidelines. 100% private — all calculations run in your browser.

Important Disclaimer: This tool provides general information based on FDA guidelines and is NOT medical advice. Only a licensed healthcare provider can determine if GLP-1 medication is appropriate for you. Always consult your doctor before starting any medication.
Ad Space

Who Qualifies for GLP-1 Weight Loss Medication?

GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) have transformed weight management treatment. The FDA has approved these medications for specific patient populations based on clinical trial data. For weight management, adults with a BMI of 30 or above (obesity) generally qualify. Adults with a BMI of 27 or above (overweight) may also qualify if they have at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. Previous unsuccessful attempts at weight loss through diet and exercise support your candidacy when speaking with a doctor.

FDA Eligibility Criteria Explained

The FDA uses Body Mass Index (BMI) as the primary screening metric for GLP-1 weight loss medications. For Wegovy and Zepbound, which are specifically approved for chronic weight management, the threshold is BMI 30+ without comorbidities or BMI 27+ with at least one qualifying comorbidity. For Ozempic and Mounjaro, which are primarily approved for type 2 diabetes management, the key criterion is a diagnosis of type 2 diabetes — BMI is secondary. These medications work by mimicking the GLP-1 hormone, which regulates appetite and blood sugar levels, leading to significant weight reduction in clinical trials.

GLP-1 Medications Available in 2026

Several GLP-1 medications are currently FDA-approved. Wegovy (semaglutide 2.4mg injection) and Zepbound (tirzepatide injection) are approved for chronic weight management. Ozempic (semaglutide injection) and Mounjaro (tirzepatide injection) are approved for type 2 diabetes but are also prescribed off-label for weight loss. The oral semaglutide 50mg tablet (Wegovy Pill) offers a needle-free option for weight management. Average weight loss ranges from 15-25% of body weight over 12-18 months, though individual results vary based on adherence, diet, and exercise habits.

Contraindications and Safety Considerations

GLP-1 medications are not appropriate for everyone. They are contraindicated during pregnancy and breastfeeding due to potential risks to the fetus. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use these medications. GLP-1 drugs are not currently approved for weight management in individuals under 18. Common side effects include nausea, vomiting, and diarrhea, which typically improve over time. Always discuss your complete medical history with your healthcare provider before starting any GLP-1 medication.

Next Steps After Checking Eligibility

If this screening suggests you may be eligible, the next step is scheduling an appointment with your healthcare provider. Bring your BMI results, list of current medications, and medical history. Your doctor may order blood work including HbA1c, lipid panel, and thyroid function tests. Insurance coverage varies — many plans now cover FDA-approved GLP-1 medications for qualifying patients. Manufacturer savings programs and telehealth providers may offer additional access options. If you do not currently meet the criteria, focus on sustainable lifestyle changes including balanced nutrition and regular physical activity, and discuss alternative options with your doctor.